Zhen Zhang, PhD

Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, New Jersey

  • 3Articles
  • 16.1KReads1
  • 2023–2026Active
  • 14Collaborators
  • 16Citations2

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

About

Zhen Zhang, PhD, is affiliated with Otsuka Pharmaceutical Development & Commercialization Inc. in Princeton, New Jersey. Zhang has published research from 2023 to 2026 focusing on the treatment of schizophrenia, schizoaffective disorders, and bipolar disorder. The work includes analyses of aripiprazole formulations for maintenance therapy and safety in diverse patient populations. Zhang frequently collaborates with authors such as Karimah S. Bell Lynum and Leslie Citrome.

Publications

JCP
NNT, NNH, and LLH for Aripiprazole Once-Monthly in Schizophrenia
Original Research

NNT, NNH, and LLH for Aripiprazole Once-Monthly in Schizophrenia

May 13, 2026

Data demonstrate a favorable benefit-risk profile for aripiprazole once-monthly 400 vs placebo in acute and maintenance treatment of schizophrenia.
, , , et al
JCP
Safety and Efficacy of Maintenance Treatment with Aripiprazole Once-Monthly in Black/African American Adults With Bipolar I Disorder
Original Research

Safety and Efficacy of Maintenance Treatment with Aripiprazole Once-Monthly in Black/African American Adults With Bipolar I Disorder

March 9, 2026

The safety and efficacy of AOM 400 were comparable between Black/African American and non-Black/African American patients with bipolar I disorder
, , , et al
JCP
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg
Original Research

Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg

September 4, 2023

A new formulation of injectable aripiprazole for administration every 2 months showed similar rates of treatment-emergent adverse events to aripiprazole once-monthly 400 mg. Patients in both groups remained clinically...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe